{"success":true,"data":{"pressRelease":{"id":"154653","rtpr_id":"nBw5G3D8ga-20260928","ticker":"ROPC","exchange":"","all_tickers":["ROPC"],"title":"Genentech Breaks Ground on $750 Million Manufacturing Expansion in Hillsboro, Oregon","author":"Business Wire","published_at":"2026-09-28T22:00:00.076Z","article_body":"Genentech Breaks Ground on $750 Million Manufacturing Expansion in Hillsboro,\nOregon\n\n\n *  Expansion adds 211,000 square feet to the site, supported by approximately\n200 construction jobs\n\n * Investment creates approximately 250 high-wage jobs pairing manufacturing\nexpertise with digital skills in AI, automation and robotics\n\n * New facility brings device fill-finish capabilities to Genentech’s\nmanufacturing network—expanding on established fill-finish operations—and\nbuilds on recent manufacturing and investment milestones in Holly Springs,\nNorth Carolina and Boston, Massachusetts\n\nGenentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today\nbroke ground on a $750 million expansion of its manufacturing facility in\nHillsboro, Oregon, advancing plans announced in August to increase capacity\nfor advanced drug delivery devices and to strengthen the company’s United\nStates manufacturing capabilities. The event marks the start of construction\nfor the 211,000-square-feet expansion, doubling the size of the existing site.\nCommercial operations are planned to begin in 2031.\n\nOnce operational, the expanded facility will add device fill-finish\ncapabilities, including the manufacturing of combination products, to\nGenentech’s U.S. manufacturing network. With flexible high- and low-volume\nfilling capabilities, the site is designed to manufacture a broad range of\nmedicines across oncology, neurology and immunology. This added capacity will\nhelp strengthen Genentech’s domestic supply chain and support reliable\naccess to medicines for patients.\n\nThe expansion will create approximately 250 high-wage manufacturing jobs. Over\nthe coming years, Genentech will recruit for specialized roles across filling\nand inspection, device assembly and packaging, cold storage, and quality\ncontrol. These roles will pair traditional manufacturing expertise with\ndigital skills in AI, automation and robotics, creating a modern workforce\nequipped to drive innovation in precision manufacturing. Construction of the\nfacility will also support approximately 200 additional construction jobs.\n\nGenentech established its Hillsboro campus in 2006. Today, the 75-acre campus\nis an important part of the company’s manufacturing network, with\ncapabilities spanning drug product manufacturing, packaging, distribution and\nindividualized therapies. The decision to expand in Hillsboro reflects\nGenentech’s continued confidence in the area’s experienced workforce,\nestablished infrastructure and manufacturing expertise, as well as the\ncompany’s longstanding partnership with the Hillsboro community and the\nstate of Oregon.\n\nThe expansion is part of Roche and Genentech’s investment commitment in U.S.\nmanufacturing and R&D and builds on recent manufacturing and investment\nmilestones in Holly Springs, North Carolina\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.gene.com%2Fmedia%2Fpress-releases%2F15122%2F2026-08-18%2Fgenentech-marks-topping-out-milestone-fo&esheet=54611039&newsitemid=20260928061898&lan=en-US&anchor=Holly+Springs%2C+North+Carolina&index=1&md5=8bdde50c73e2fc8f21817a29710affdd)\nand Boston, Massachusetts\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.gene.com%2Fmedia%2Fpress-releases%2F15125%2F2026-09-17%2Fgenentech-and-roche-announce-grand-openi&esheet=54611039&newsitemid=20260928061898&lan=en-US&anchor=Boston%2C+Massachusetts&index=2&md5=395b666352a258fb98a5698a1ea65429)\n. Together, these investments expand an end-to-end U.S. footprint spanning\nresearch, development and manufacturing and reflect the companies’ long-term\ncommitment to American scientific innovation. Roche and Genentech have\napproximately 25,000 employees in the U.S., with 15 R&D centers and 13\nmanufacturing sites.\n\nGenentech CEO Ashley Magargee:\n\n“Breaking ground in Hillsboro turns our commitment into action. For 20\nyears, the talented team here has played an important role in manufacturing\nand delivering medicines for patients, and this expansion builds on that\nstrong foundation. As construction begins we are one step closer to bringing\ndevice fill-finish manufacturing to Hillsboro, strengthening our domestic\nsupply chain and investing in the people and infrastructure that will help us\ndeliver the medicines of the future.”\n\nSusanne Hundsbaek-Pedersen, Roche EVP of Pharma Technical Operations:\n\n“The medicines in our pipeline increasingly include devices that improve\ndelivery convenience and our manufacturing network is evolving to service\nthese requirements. This manufacturing expansion in Hillsboro will add\ncapabilities that our future portfolio will need, along with the flexibility\nto adapt as patient needs change. The site will feature advanced digital\ntechnology, AI, automation, and robotics to optimize production, as well as an\nexact digital twin for real-time monitoring and continuous improvement.\nCombined with the expertise already on this site, it will strengthen how we\nsupply medicines across our global network.”\n\nTina Kotek, Governor of Oregon:\n\n“Today, we’re seeing a major investment in Oregon move from plans on paper\nto breaking ground. Genentech’s continued growth in Hillsboro demonstrates\nthe strength of Oregon’s workforce and our ability to support advanced\nmanufacturing that is important to both our state and the country. This\nproject will create new opportunities for Oregonians while strengthening\nHillsboro’s role in the future of U.S. medicine manufacturing.”\n\nBeach Pace, Mayor of Hillsboro:\n\n“Today’s groundbreaking is an exciting moment for Hillsboro and a sign of\nwhat’s ahead for our city. Projects of this scale are made possible by\nstrong partnerships across the community, from the people who will build this\nfacility to the local organizations and institutions that support a skilled\nworkforce that will staff the facility, and of course, between the City of\nHillsboro and Genentech. We look forward to this next chapter taking shape and\ncontinuing to build Hillsboro’s and Genentech’s future together.”\n\nAbout Genentech\n\nFounded 50 years ago, Genentech is a leading biotechnology company that\ndiscovers, develops, manufactures and commercializes medicines to treat\npatients with serious and life-threatening medical conditions. The company, a\nmember of the Roche Group, has headquarters in South San Francisco,\nCalifornia. For additional information about the company, please visit\nhttp://www.gene.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.gene.com%2F&esheet=54611039&newsitemid=20260928061898&lan=en-US&anchor=http%3A%2F%2Fwww.gene.com&index=3&md5=2b6207d8f1a5db342ce7189261c4fe89)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260928061898/en/\n(https://www.businesswire.com/news/home/20260928061898/en/)\n\nGenentech Media Relations: (650) 467-6800\n\n\n\nTracy Furey\n\nfurey.tracy@gene.com \n(mailto:furey.tracy@gene.com) \n(908) 458-3282\n\n\n\nGaby Witte\n\nwitte.gaby@gene.com \n(mailto:witte.gaby@gene.com) \n(707) 303-5637\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw5G3D8ga-20260928","title":"Genentech Breaks Ground on $750 Million Manufacturing Expansion in Hillsboro, Oregon","author":"Business Wire","ticker":"ROPC","created":"2026-09-28T22:00:00.076Z","tickers":["ROPC"],"exchange":"","article_body":"Genentech Breaks Ground on $750 Million Manufacturing Expansion in Hillsboro,\nOregon\n\n\n *  Expansion adds 211,000 square feet to the site, supported by approximately\n200 construction jobs\n\n * Investment creates approximately 250 high-wage jobs pairing manufacturing\nexpertise with digital skills in AI, automation and robotics\n\n * New facility brings device fill-finish capabilities to Genentech’s\nmanufacturing network—expanding on established fill-finish operations—and\nbuilds on recent manufacturing and investment milestones in Holly Springs,\nNorth Carolina and Boston, Massachusetts\n\nGenentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today\nbroke ground on a $750 million expansion of its manufacturing facility in\nHillsboro, Oregon, advancing plans announced in August to increase capacity\nfor advanced drug delivery devices and to strengthen the company’s United\nStates manufacturing capabilities. The event marks the start of construction\nfor the 211,000-square-feet expansion, doubling the size of the existing site.\nCommercial operations are planned to begin in 2031.\n\nOnce operational, the expanded facility will add device fill-finish\ncapabilities, including the manufacturing of combination products, to\nGenentech’s U.S. manufacturing network. With flexible high- and low-volume\nfilling capabilities, the site is designed to manufacture a broad range of\nmedicines across oncology, neurology and immunology. This added capacity will\nhelp strengthen Genentech’s domestic supply chain and support reliable\naccess to medicines for patients.\n\nThe expansion will create approximately 250 high-wage manufacturing jobs. Over\nthe coming years, Genentech will recruit for specialized roles across filling\nand inspection, device assembly and packaging, cold storage, and quality\ncontrol. These roles will pair traditional manufacturing expertise with\ndigital skills in AI, automation and robotics, creating a modern workforce\nequipped to drive innovation in precision manufacturing. Construction of the\nfacility will also support approximately 200 additional construction jobs.\n\nGenentech established its Hillsboro campus in 2006. Today, the 75-acre campus\nis an important part of the company’s manufacturing network, with\ncapabilities spanning drug product manufacturing, packaging, distribution and\nindividualized therapies. The decision to expand in Hillsboro reflects\nGenentech’s continued confidence in the area’s experienced workforce,\nestablished infrastructure and manufacturing expertise, as well as the\ncompany’s longstanding partnership with the Hillsboro community and the\nstate of Oregon.\n\nThe expansion is part of Roche and Genentech’s investment commitment in U.S.\nmanufacturing and R&D and builds on recent manufacturing and investment\nmilestones in Holly Springs, North Carolina\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.gene.com%2Fmedia%2Fpress-releases%2F15122%2F2026-08-18%2Fgenentech-marks-topping-out-milestone-fo&esheet=54611039&newsitemid=20260928061898&lan=en-US&anchor=Holly+Springs%2C+North+Carolina&index=1&md5=8bdde50c73e2fc8f21817a29710affdd)\nand Boston, Massachusetts\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.gene.com%2Fmedia%2Fpress-releases%2F15125%2F2026-09-17%2Fgenentech-and-roche-announce-grand-openi&esheet=54611039&newsitemid=20260928061898&lan=en-US&anchor=Boston%2C+Massachusetts&index=2&md5=395b666352a258fb98a5698a1ea65429)\n. Together, these investments expand an end-to-end U.S. footprint spanning\nresearch, development and manufacturing and reflect the companies’ long-term\ncommitment to American scientific innovation. Roche and Genentech have\napproximately 25,000 employees in the U.S., with 15 R&D centers and 13\nmanufacturing sites.\n\nGenentech CEO Ashley Magargee:\n\n“Breaking ground in Hillsboro turns our commitment into action. For 20\nyears, the talented team here has played an important role in manufacturing\nand delivering medicines for patients, and this expansion builds on that\nstrong foundation. As construction begins we are one step closer to bringing\ndevice fill-finish manufacturing to Hillsboro, strengthening our domestic\nsupply chain and investing in the people and infrastructure that will help us\ndeliver the medicines of the future.”\n\nSusanne Hundsbaek-Pedersen, Roche EVP of Pharma Technical Operations:\n\n“The medicines in our pipeline increasingly include devices that improve\ndelivery convenience and our manufacturing network is evolving to service\nthese requirements. This manufacturing expansion in Hillsboro will add\ncapabilities that our future portfolio will need, along with the flexibility\nto adapt as patient needs change. The site will feature advanced digital\ntechnology, AI, automation, and robotics to optimize production, as well as an\nexact digital twin for real-time monitoring and continuous improvement.\nCombined with the expertise already on this site, it will strengthen how we\nsupply medicines across our global network.”\n\nTina Kotek, Governor of Oregon:\n\n“Today, we’re seeing a major investment in Oregon move from plans on paper\nto breaking ground. Genentech’s continued growth in Hillsboro demonstrates\nthe strength of Oregon’s workforce and our ability to support advanced\nmanufacturing that is important to both our state and the country. This\nproject will create new opportunities for Oregonians while strengthening\nHillsboro’s role in the future of U.S. medicine manufacturing.”\n\nBeach Pace, Mayor of Hillsboro:\n\n“Today’s groundbreaking is an exciting moment for Hillsboro and a sign of\nwhat’s ahead for our city. Projects of this scale are made possible by\nstrong partnerships across the community, from the people who will build this\nfacility to the local organizations and institutions that support a skilled\nworkforce that will staff the facility, and of course, between the City of\nHillsboro and Genentech. We look forward to this next chapter taking shape and\ncontinuing to build Hillsboro’s and Genentech’s future together.”\n\nAbout Genentech\n\nFounded 50 years ago, Genentech is a leading biotechnology company that\ndiscovers, develops, manufactures and commercializes medicines to treat\npatients with serious and life-threatening medical conditions. The company, a\nmember of the Roche Group, has headquarters in South San Francisco,\nCalifornia. For additional information about the company, please visit\nhttp://www.gene.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.gene.com%2F&esheet=54611039&newsitemid=20260928061898&lan=en-US&anchor=http%3A%2F%2Fwww.gene.com&index=3&md5=2b6207d8f1a5db342ce7189261c4fe89)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260928061898/en/\n(https://www.businesswire.com/news/home/20260928061898/en/)\n\nGenentech Media Relations: (650) 467-6800\n\n\n\nTracy Furey\n\nfurey.tracy@gene.com \n(mailto:furey.tracy@gene.com) \n(908) 458-3282\n\n\n\nGaby Witte\n\nwitte.gaby@gene.com \n(mailto:witte.gaby@gene.com) \n(707) 303-5637\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-09-28T22:00:00.139252424Z","server_sent_at_ms":1790632800139},"received_at":"2026-09-28T22:00:00.357Z","source_url":"https://www.businesswire.com/news/home/20260928061898/en/"},"analysis":{"id":"143411","press_release_id":"154653","analysis_json":{"industry":null,"redFlags":["announcement relates to Genentech/Roche, not the FILER (ROPC); relevance to the input ticker is unclear"],"eventType":"operations_update","narrative":"Genentech broke ground on a $750 million expansion of its Hillsboro, Oregon manufacturing site, adding 211,000 square feet and roughly doubling the existing campus.\n\nThe expanded facility will add device fill-finish and combination-product capabilities across oncology, neurology and immunology, with commercial operations planned for 2031.\n\nThe project creates about 250 high-wage manufacturing jobs plus 200 construction jobs and forms part of Roche and Genentech's broader U.S. manufacturing and R&D investment push alongside sites in Holly Springs, North Carolina and Boston.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Corporate capex news from Roche Group's Genentech; no direct bearing on ROPC -- suppress unless ROPC relationship is clarified."},"keyFigures":{"customDimensions":{"us_employees":25000,"investment_usd":750000000,"us_rnd_centers":15,"expansion_sq_ft":211000,"construction_jobs":200,"new_manufacturing_jobs":250,"us_manufacturing_sites":13,"commercial_operations_start":"2031"}},"quotedText":"Breaking ground in Hillsboro turns our commitment into action.","namedEntities":{"people":[{"name":"Ashley Magargee","role":"CEO of Genentech"},{"name":"Susanne Hundsbaek-Pedersen","role":"Roche EVP of Pharma Technical Operations"},{"name":"Tina Kotek","role":"Governor of Oregon"},{"name":"Beach Pace","role":"Mayor of Hillsboro"}],"products":[],"companies":[{"name":"Genentech","relationship":"subject of the announcement; member of Roche Group"},{"name":"Roche","ticker":"RHHBY","relationship":"parent company of Genentech"}],"dollarAmounts":[{"amount":"$750 million","context":"Hillsboro, Oregon manufacturing expansion investment"}]},"materialImpact":{"score":1,"reasoning":"This is a Genentech/Roche corporate groundbreaking announcement; it does not involve the FILER (ROPC) operationally or financially. No direct economic impact on the input ticker is disclosed."},"tickerRelevance":{"others":[{"ticker":"RHHBY","relevance":"other"},{"ticker":"RO","relevance":"other"}],"primary":"ROPC"},"globalImportance":22,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap/unclear filer","eventGravity":"corporate facility expansion","filerRelevance":"negligible -- filer not the subject of the release","householdBrandBoost":"Genentech/Roche brand recognition"}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Genentech broke ground on a $750 million expansion of its Hillsboro, Oregon manufacturing site, adding 211,000 square feet and roughly doubling the existing campus.\n\nThe expanded facility will add device fill-finish and combination-product capabilities across oncology, neurology and immunology, with commercial operations planned for 2031.\n\nThe project creates about 250 high-wage manufacturing jobs plus 200 construction jobs and forms part of Roche and Genentech's broader U.S. manufacturing and R&D investment push alongside sites in Holly Springs, North Carolina and Boston.","key_figures":{"customDimensions":{"us_employees":25000,"investment_usd":750000000,"us_rnd_centers":15,"expansion_sq_ft":211000,"construction_jobs":200,"new_manufacturing_jobs":250,"us_manufacturing_sites":13,"commercial_operations_start":"2031"}},"named_entities":{"people":[{"name":"Ashley Magargee","role":"CEO of Genentech"},{"name":"Susanne Hundsbaek-Pedersen","role":"Roche EVP of Pharma Technical Operations"},{"name":"Tina Kotek","role":"Governor of Oregon"},{"name":"Beach Pace","role":"Mayor of Hillsboro"}],"products":[],"companies":[{"name":"Genentech","relationship":"subject of the announcement; member of Roche Group"},{"name":"Roche","ticker":"RHHBY","relationship":"parent company of Genentech"}],"dollarAmounts":[{"amount":"$750 million","context":"Hillsboro, Oregon manufacturing expansion investment"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-28T22:00:06.383Z","global_importance":22,"audience_relevance":12,"importance_components":{"tickerTier":"micro-cap/unclear filer","eventGravity":"corporate facility expansion","filerRelevance":"negligible -- filer not the subject of the release","householdBrandBoost":"Genentech/Roche brand recognition"}},"durationMs":6002,"modelName":"glm-5.3-flashx"}}